HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women
HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer
Increasing the dose intensity of chemotherapy may lower the risk of breast cancer recurrence and death
The reality of pancreatic cancer
Personalised medicine for inherited breast cancer
Lung cancer screening across Europe
Multi gene panels for cancer prevention in Italy
Personalised medicine in Lombardy
Personalised haematology treatments
The importance of increasing biomarker understanding
Editor's Choice for November 2017